Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tonix Pharmaceuticals Holding (TNXP) Equity Ratio (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Equity Ratio over the past 3 years, most recently at 0.88 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.88 for Q4 2025, up 3.23% from a year ago — trailing twelve months through Dec 2025 was 0.88 (up 3.23% YoY), and the annual figure for FY2025 was 0.88, up 3.23%.
  • Equity Ratio for Q4 2025 was 0.88 at Tonix Pharmaceuticals Holding, down from 0.92 in the prior quarter.
  • Over the last five years, Equity Ratio for TNXP hit a ceiling of 0.94 in Q1 2025 and a floor of 0.6 in Q2 2024.
  • Median Equity Ratio over the past 3 years was 0.87 (2023), compared with a mean of 0.84.
  • Biggest five-year swings in Equity Ratio: tumbled 31.9% in 2024 and later soared 49.73% in 2025.
  • Tonix Pharmaceuticals Holding's Equity Ratio stood at 0.68 in 2023, then rose by 25.4% to 0.86 in 2024, then rose by 3.23% to 0.88 in 2025.
  • The last three reported values for Equity Ratio were 0.88 (Q4 2025), 0.92 (Q3 2025), and 0.9 (Q2 2025) per Business Quant data.